Baxter Initiates Voluntary Recall of Potassium Chloride Injection
Baxter International initiated a US voluntary recall of one lot of potassium chloride injection due to mislabeled shipping carton.
Baxter International announced on Sept. 16, 2014 that it is voluntarily recalling one lot of Potassium Chloride Injection 10mEq per 100mL, product code 2B0826, lot P318220, NDC #0338-0709-48 distributed to the hospital/pharmacy/nurse level for the treatment of potassium deficiency. The recall is being initiated due to a labeling error on the shipping cartons in a single lot, which was identified by three customers. Shipping cartons labeled for this specific lot number of Potassium Chloride Injection may contain units of Gentamicin Sulfate Injection, an antibacterial drug, 80 mg in 100 mL, product code 2B0862.
As both products are packaged in 100 mL containers, have similar code numbers, and red labeling on the front panel, there is a potential risk of medication error or delay in therapy for patients that require high-concentration potassium chloride.
The lot was distributed between May 26, 2014 and August 8, 2014. Any healthcare professionals with an existing lot are advised to carefully review the product label before administering.
Source: FDA
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
